ARLINGTON, Va., Feb. 1 /PRNewswire/ -- Longtime collaborators CONRAD and
the Biosyn Division of Cellegy Pharmaceuticals, Inc. today announced a non-
exclusive licensing agreement to research and develop Biosyn-patented
microbicides for the prevention of HIV and other sexually transmitted
The three microbicides covered under the agreement are in various stages
of development and work under different mechanisms of action. They include:
Savvy, which is currently in Phase III clinical trials in the U.S. and Africa;
UC781 which is in expanded Phase II trials in the U.S. and Thailand and
Cyanovirin-N which is in preclinical testing.
Henry Gabelnick, Ph.D., executive director of CONRAD says, "This agreement
is great news for everyone interested in developing an effective microbicide.
The more partnerships we have like this one, the better our potential is for
getting an effective product ready for distribution."
"I am delighted for our two organizations to enter into this agreement.
We have collaborated for many years on all aspects of our microbicide
development programs, and we have a deep respect for each other's knowledge
and expertise. With CONRAD, we feel we have a capable and experienced partner
to work with us toward approval of these critically important products," said
Anne-Marie Corner, Senior Vice President of Cellegy Pharmaceuticals.
Currently, the highest rates of infection in women are in sub-Saharan
Africa and rates are increasing in women in South and Southeast Asia.
CONRAD has been involved in the research of nearly every microbicide
currently in clinical trials. They are currently managing a second Phase III
trial of a microbicide called Ushercell in Uganda and South Africa, Benin,
Burkina Faso and two centers in India. The trials will evaluate Ushercell for
the prevention of HIV infection among 2,574 adult women at high risk of
acquiring HIV. This study will also assess incidence of genital gonorrhea and
CONRAD is a cooperating agency of USAID committed to improving
reproductive health by expanding the contraceptive choices of women and men
and by helping to prevent the transmission of HIV/AIDS and other sexually
transmitted diseases. CONRAD is administered through the Department of
Obstetrics and Gynecology at Eastern Virginia Medical School (EVMS) in
Norfolk, VA, with the main office located in Arlington, VA.
Cellegy Pharmaceuticals is a specialty biopharmaceutical company that
develops and commercializes prescription drugs for the treatment of women's
health care conditions, including sexual dysfunction, HIV prevention; and,
gastrointestinal disorders. Biosyn, Inc is a wholly owned subsidiary of
Cellegesic(TM) (nitroglycerin ointment), branded Rectogesic(R) outside the
United States, is approved and is being marketed in the United Kingdom by
ProStrakan, for the treatment of pain associated with chronic anal fissures.
A similar formulation of Rectogesic is currently being sold in Australia, New
Zealand, Singapore and South Korea.
Fortigel(TM) (testosterone gel), branded Tostrex(R) outside the United
States, is marketed in Sweden for the treatment of male hypogonadism also by
ProStrakan. Approvals of Rectogesic and Tostrex by the other member states of
the European Union are being sought through the Mutual Recognition Procedure.
Web Site: http://www.conrad.org